Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma

PURPOSE: Several studies have evaluated the utility of extrapolating the Calvert formula in calculating carboplatin (CBDCA) dosages in solid tumours; however, data regarding haematological cancers are less. Therefore, we conducted a preliminary study of the utility of extrapolating the Calvert formu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Tomono, Ayana, Ito, Kaori, Hayashi, Takahiro, Ando, Maiko, Ando, Yosuke, Tsuge, Masahiro, Okamoto, Akinao, Inaguma, Yoko, Okamoto, Masataka, Emi, Nobuhiko, Yamada, Shigeki
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4965483/
https://ncbi.nlm.nih.gov/pubmed/27324021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3076-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars